Terminated × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Clear all FLUBUTBI
Phase 3 Terminated
53 enrolled 11 charts
Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
Phase 1 Terminated
20 enrolled
Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
Phase 2 Terminated
51 enrolled 8 charts
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
Phase 1 Terminated
84 enrolled
Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
Phase 2 Terminated
25 enrolled 8 charts
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Phase 2 Terminated
31 enrolled 18 charts
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Phase 2 Terminated
150 enrolled
Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
Phase 1 Terminated
8 enrolled
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
Phase 1/2 Terminated
9 enrolled 11 charts
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
Phase 2 Terminated
9 enrolled 11 charts
PALERMO
Phase 3 Terminated
80 enrolled
Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib
Phase 2 Terminated
14 enrolled
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
Phase 2 Terminated
1 enrolled 11 charts
Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia
Phase 1 Terminated
19 enrolled
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
Phase 1/2 Terminated
48 enrolled
An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia
Phase 1 Terminated
37 enrolled 14 charts
OMNI
Terminated
3 enrolled
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Phase 1 Terminated
2 enrolled
PONS
Phase 2 Terminated
18 enrolled
DC Vaccination in CML
Phase 1/2 Terminated
1 enrolled
Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia
Phase 2 Terminated
12 enrolled 8 charts
Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications
Phase NA Terminated
6 enrolled
T-cell Depleted Alternative Donor Transplantation
Phase 2 Terminated
53 enrolled 14 charts
IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT
Phase 1 Terminated
6 enrolled
Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors
Phase 4 Terminated
163 enrolled 27 charts
OPTIC-2L
Phase 3 Terminated
44 enrolled 22 charts
A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)
Phase 1/2 Terminated
10 enrolled 28 charts
AFR22
Phase 2 Terminated
19 enrolled 4 charts
Phase I Study of Milatuzumab for Graft Versus Host Disease
Phase 1 Terminated
12 enrolled
MACS0254
Phase 2 Terminated
18 enrolled 12 charts
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase
Phase 2 Terminated
27 enrolled 14 charts
Stem Cell Transplant for Hematological Malignancy
Phase NA Terminated
330 enrolled 25 charts
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
Phase 2 Terminated
3 enrolled 17 charts
Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant
Phase 1 Terminated
13 enrolled
Cord Blood
Phase 1/2 Terminated
3 enrolled 8 charts
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases
Phase NA Terminated
2 enrolled 11 charts
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
Phase 1 Terminated
12 enrolled
MACS1532
Phase 3 Terminated
7 enrolled 4 charts
DECLINE
Phase 3 Terminated
14 enrolled
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
Phase 2 Terminated
4 enrolled 13 charts
Post Transplant Donor Lymphocyte Infusion
Phase 2 Terminated
57 enrolled 13 charts
A Study for Patients With Acute Leukemia
Phase 1 Terminated
33 enrolled 18 charts
Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
Phase 2 Terminated
32 enrolled
Bortezomib in Treating Patients With Chronic Myelogenous Leukemia
Phase 2 Terminated
7 enrolled
Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
Phase 2 Terminated
7 enrolled 5 charts
PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron
Phase 2 Terminated
1 enrolled
Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)
Phase 2/3 Terminated
3 enrolled
Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C
Phase 2 Terminated
117 enrolled 6 charts
Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT
Phase 1 Terminated
1 enrolled
Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)
Phase 2 Terminated
5 enrolled 3 charts